FGF21 inhibits apolipoprotein(a) expression in HepG2 cells via the FGFR1-ERK1/2-Elk-1 pathway

Molecular and Cellular Biochemistry

Volumn 393, Issue 1-2, 2014, Pages 33-42

  Lin, Xiaolong ^a   Li, Guohua ^a   He, Xinglan ^a   Ma, Xiaofeng ^a   Zhang, Kai ^a   Zhang, Hai ^a   Zeng, Gaofeng ^a   Wang, Zuo ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Apolipoprotein(a); Fibroblast growth factor receptor 1; Fibroblast growth factor 21; Lipoprotein(a)

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; APOLIPOPROTEIN A; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ELK 1; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ARTICLE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ADIPOCYTE; BIOSYNTHESIS; GENETICS; LIPID METABOLISM; LIVER CELL; METABOLISM; PATHOLOGY;

ADIPOCYTES; APOPROTEIN(A); ETS-DOMAIN PROTEIN ELK-1; FIBROBLAST GROWTH FACTORS; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIPID METABOLISM; MAP KINASE SIGNALING SYSTEM; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION;

EID: 84903477340     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2044-0     Document Type: Article

References (31)

1. Berg K (1963) A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 59:369-382
2. Zlatohlávek L, Zídková K, Vrablík M, Haas T, Prusíková M, Svobodová H, Ceska R (2008) Lipoprotein(a) and its position among other risk factors of atherosclerosis. Physiol Res 57:777-783
3. Nielsen LB, Juul K, Nordestgaard BG (1998) Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler Thromb Vasc Biol 18:641-649 (Pubitemid 28177906)
4. Sotiriou SN, Orlova VV, Al-Fakhri N, Ihanus E, Economopoulou M, Isermann B, Bdeir K, Nawroth PP, Preissner KT, Gahmberg CG, Koschinsky ML, Chavakis T (2006) Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J 20:559-561 (Pubitemid 46671249)
5. Pedersen TX, McCormick SP, Tsimikas S, Bro S, Nielsen LB (2010) Lipoprotein(a) accelerates atherosclerosis in uremic mice. J Lipid Res 51:2967-2975
6. Brunner C, Kraft HG, Utermann G, Muller HJ (1993) Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci USA 90:11643-11647
7. Becker L, McLeod RS, Marcovina SM, Yao Z, Koschinsky ML (2001) Identification of a critical lysine residue in apolipoprotein B-100 that mediates noncovalent interaction with apolipoprotein (a). J Biol Chem 276:36155-36162
8. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132-137 (Pubitemid 17158542)
9. Utermann G, Duba C, Menzel HJ (1988) Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes. Hum Genet 78:47-50 (Pubitemid 18039524)
10. Norata GD, Ballantyne CM, Catapano AL (2013) New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J 34:1783-1789
11. Dieplinger H, Utermann G (1999) The seventh myth of lipoprotein (a): where and how is it assembled. Curr Opin Lipidol 10:275-283 (Pubitemid 29405918)
12. Bonen DK, Hausman AM, Hadjiagapiou C, Skarosi SF, Davidson NO (1997) Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). J Biol Chem 272:5659-5667 (Pubitemid 27102393)
13. White AL, Rainwater DL, Hixson JE, Estlack LE, Lanford RE (1994) Intracellular processing of apo(a) in primary baboon hepatocytes. Chem Phys Lipids 67-68(123-133):114
14. Li H, Zhang J, Jia W (2013) Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology. Front Med 7:25-30
15. Murata Y, Konishi M, Itoh N (2011) FGF21 as an endocrine regulator in lipid metabolism: from molecular evolution to physiology and pathophysiology. J Nutr Metab 2011:981315
16. Kharitonenkov A, Larsen P (2011) FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab 22:81-86
17. Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, Lu Z, Gao M, Bao Y, Jia W (2013) Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 12:124
18. Cong WT, Ling J, Tian HS, Ling R, Wang Y, Huang BB, Zhao T, Duan YM, Jin LT, Li XK (2013) Proteomic study on the protective mechanism of fibroblast growth factor 21 to ischemia-reperfusion injury. Can J Physiol Pharmacol 91:973-984
19. Reitman ML (2013) FGF21 mimetic shows therapeutic promise. Cell Metab 18:307-309
20. Ming AY, Yoo E, Vorontsov EN, Altamentova SM, Kilkenny DM, Rocheleau JV (2012) Dynamics and distribution of Klothob (KLB) and fibroblast growth factor receptor-1 (FGFR1) in living cells reveal the fibroblast growth factor-21 (FGF21)-induced receptor complex. J Biol Chem 287:19997-20006
21. Bookout AL, de Groot MH, Owen BM, Lee S, Gautron L, Lawrence HL, Ding X, Elmquist JK, Takahashi JS, Mangelsdorf DJ, Kliewer SA (2013) FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 19:1147-1152
22. Cuevas-Ramos D, Aguilar-Salinas CA, Gómez-Pérez FJ (2012) Metabolic actions of fibroblast growth factor 21. Curr Opin Pediatr 24:523-529
23. Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, Flier JS, Kharitonenkov A, Spiegelman BM, Maratos-Flier E (2011) Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 152:2996-3004
24. Chennamsetty I, Claudel T, Kostner KM, Trauner M, Kostner GM (2012) Gene expression APOA FGF19 signaling cascade suppresses. Arterioscler Thromb Vasc Biol 32:1220-1227
25. Wei DH, Zhang XL, Wang R, Zeng JF, Zhang K, Yang J, Li S, Lin XL, Jiang ZS, Wang GX, Wang Z (2013) Oxidized lipoprotein(a) increases endothelial cell monolayer permeability via ROS generation. Lipids 48:579-586
26. Panek RL, Lu GH, Dahring TK, Batley BL, Connolly C, Hamby JM, Brown KJ (1998) In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J Pharmacol Exp Ther 286:569-577 (Pubitemid 28318035)
27. Nygaard EB, Vienberg SG, Ørskov C, Hansen HS, Andersen B (2012) Metformin stimulates FGF21 expression in primary hepatocytes. Exp Diabetes Res 2012:465282
28. Adams AC, Kharitonenkov A (2013) FGF21 drives a shift in adipokine tone to restore metabolic health. Aging (Albany NY) 5:386-387
29. Chennamsetty I, Claudel T, Kostner KM, Baghdasaryan A, Kratky D, Levak-Frank S, Frank S, Gonzalez FJ, Trauner M, Kostner GM (2011) Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest 121:3724-3734
30. Yie J, Hecht R, Patel J, Stevens J, Wang W, Hawkins N, Steavenson S, Smith S, Winters D, Fisher S, Cai L, Belouski E, Chen C, Michaels ML, Li YS, Lindberg R, Wang M, Véniant M, Xu J (2009) FGF21N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 583:19-24
31. Gaich G, Chien JY, Fu H, Glass1 LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HE, David E (2013) Moller the effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metabolism 18:333-340